A preliminary quality of life questionnaire-bronchiectasis

A patient-reported outcome measure for bronchiectasis

Alexandra Quittner, Kristen K. Marciel, Matthias A Salathe, Anne E. O'Donnell, Mark H. Gotfried, Jonathan S. Ilowite, Mark L. Metersky, Patrick A. Flume, Sandra A. Lewis, Matthew McKevitt, A. Bruce Montgomery, Thomas G. O'Riordan, Alan F. Barker

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

BACKGROUND: The Quality of Life Questionnaire-Bronchiectasis (QOL-B) is the first diseasespecific, patient-reported outcome measure for patients with bronchiectasis. Content validity, cognitive testing, responsivity to open-label treatment, and psychometric analyses are presented. METHODS: Reviews of literature, existing measures, and physician input were used to generate the initial QOL-B. Modifications following preliminary cognitive testing (N 5 35 patients with bronchiectasis) generated version (V) 1.0. An open-ended patient interview study (N 5 28) provided additional information and was content analyzed to derive saturation matrices, which summarized all disease-related topics mentioned by each participant. This resulted in QOL-B V2.0. Psychometric analyses were carried out using results from an open-label phase 2 trial, in which 89 patients were enrolled and treated with aztreonam for inhalation solution. Responsivity to open-label treatment was observed. Additional analyses generated QOL-B V3.0, with 37 items on eight scales: respiratory symptoms; physical, role, emotional, and social functioning; vitality; health perceptions; and treatment burden. For each scale, scores are standardized on a 0-to-100-point scale; higher scores indicate better health-related quality of life. No total score is calculated. A final cognitive testing study (N 5 40) resulted in a minor change to one social functioning scale item (QOL-B V3.1). RESULTS: Content validity, cognitive testing, responsivity to open-label treatment, and initial psychometric analyses supported QOL-B items and structure. CONCLUSIONS: This interim QOL-B is a promising tool for evaluating the efficacy of new therapies for patients with bronchiectasis and for measuring symptoms, functioning, and quality of life in these patients on a routine basis. A final psychometric validation study is needed and is forthcoming. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT00805025; URL: www.clinicaltrials.gov

Original languageEnglish
Pages (from-to)437-448
Number of pages12
JournalChest
Volume146
Issue number2
DOIs
StatePublished - Jan 1 2014

Fingerprint

Bronchiectasis
Quality of Life
Psychometrics
Aztreonam
Therapeutics
Patient Reported Outcome Measures
Surveys and Questionnaires
Validation Studies
Inhalation
Interviews
Physicians
Health

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Quittner, A., Marciel, K. K., Salathe, M. A., O'Donnell, A. E., Gotfried, M. H., Ilowite, J. S., ... Barker, A. F. (2014). A preliminary quality of life questionnaire-bronchiectasis: A patient-reported outcome measure for bronchiectasis. Chest, 146(2), 437-448. https://doi.org/10.1378/chest.13-1891

A preliminary quality of life questionnaire-bronchiectasis : A patient-reported outcome measure for bronchiectasis. / Quittner, Alexandra; Marciel, Kristen K.; Salathe, Matthias A; O'Donnell, Anne E.; Gotfried, Mark H.; Ilowite, Jonathan S.; Metersky, Mark L.; Flume, Patrick A.; Lewis, Sandra A.; McKevitt, Matthew; Montgomery, A. Bruce; O'Riordan, Thomas G.; Barker, Alan F.

In: Chest, Vol. 146, No. 2, 01.01.2014, p. 437-448.

Research output: Contribution to journalArticle

Quittner, A, Marciel, KK, Salathe, MA, O'Donnell, AE, Gotfried, MH, Ilowite, JS, Metersky, ML, Flume, PA, Lewis, SA, McKevitt, M, Montgomery, AB, O'Riordan, TG & Barker, AF 2014, 'A preliminary quality of life questionnaire-bronchiectasis: A patient-reported outcome measure for bronchiectasis', Chest, vol. 146, no. 2, pp. 437-448. https://doi.org/10.1378/chest.13-1891
Quittner A, Marciel KK, Salathe MA, O'Donnell AE, Gotfried MH, Ilowite JS et al. A preliminary quality of life questionnaire-bronchiectasis: A patient-reported outcome measure for bronchiectasis. Chest. 2014 Jan 1;146(2):437-448. https://doi.org/10.1378/chest.13-1891
Quittner, Alexandra ; Marciel, Kristen K. ; Salathe, Matthias A ; O'Donnell, Anne E. ; Gotfried, Mark H. ; Ilowite, Jonathan S. ; Metersky, Mark L. ; Flume, Patrick A. ; Lewis, Sandra A. ; McKevitt, Matthew ; Montgomery, A. Bruce ; O'Riordan, Thomas G. ; Barker, Alan F. / A preliminary quality of life questionnaire-bronchiectasis : A patient-reported outcome measure for bronchiectasis. In: Chest. 2014 ; Vol. 146, No. 2. pp. 437-448.
@article{ffb12ac3be17487b8b0a4de631f02f01,
title = "A preliminary quality of life questionnaire-bronchiectasis: A patient-reported outcome measure for bronchiectasis",
abstract = "BACKGROUND: The Quality of Life Questionnaire-Bronchiectasis (QOL-B) is the first diseasespecific, patient-reported outcome measure for patients with bronchiectasis. Content validity, cognitive testing, responsivity to open-label treatment, and psychometric analyses are presented. METHODS: Reviews of literature, existing measures, and physician input were used to generate the initial QOL-B. Modifications following preliminary cognitive testing (N 5 35 patients with bronchiectasis) generated version (V) 1.0. An open-ended patient interview study (N 5 28) provided additional information and was content analyzed to derive saturation matrices, which summarized all disease-related topics mentioned by each participant. This resulted in QOL-B V2.0. Psychometric analyses were carried out using results from an open-label phase 2 trial, in which 89 patients were enrolled and treated with aztreonam for inhalation solution. Responsivity to open-label treatment was observed. Additional analyses generated QOL-B V3.0, with 37 items on eight scales: respiratory symptoms; physical, role, emotional, and social functioning; vitality; health perceptions; and treatment burden. For each scale, scores are standardized on a 0-to-100-point scale; higher scores indicate better health-related quality of life. No total score is calculated. A final cognitive testing study (N 5 40) resulted in a minor change to one social functioning scale item (QOL-B V3.1). RESULTS: Content validity, cognitive testing, responsivity to open-label treatment, and initial psychometric analyses supported QOL-B items and structure. CONCLUSIONS: This interim QOL-B is a promising tool for evaluating the efficacy of new therapies for patients with bronchiectasis and for measuring symptoms, functioning, and quality of life in these patients on a routine basis. A final psychometric validation study is needed and is forthcoming. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT00805025; URL: www.clinicaltrials.gov",
author = "Alexandra Quittner and Marciel, {Kristen K.} and Salathe, {Matthias A} and O'Donnell, {Anne E.} and Gotfried, {Mark H.} and Ilowite, {Jonathan S.} and Metersky, {Mark L.} and Flume, {Patrick A.} and Lewis, {Sandra A.} and Matthew McKevitt and Montgomery, {A. Bruce} and O'Riordan, {Thomas G.} and Barker, {Alan F.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1378/chest.13-1891",
language = "English",
volume = "146",
pages = "437--448",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "2",

}

TY - JOUR

T1 - A preliminary quality of life questionnaire-bronchiectasis

T2 - A patient-reported outcome measure for bronchiectasis

AU - Quittner, Alexandra

AU - Marciel, Kristen K.

AU - Salathe, Matthias A

AU - O'Donnell, Anne E.

AU - Gotfried, Mark H.

AU - Ilowite, Jonathan S.

AU - Metersky, Mark L.

AU - Flume, Patrick A.

AU - Lewis, Sandra A.

AU - McKevitt, Matthew

AU - Montgomery, A. Bruce

AU - O'Riordan, Thomas G.

AU - Barker, Alan F.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - BACKGROUND: The Quality of Life Questionnaire-Bronchiectasis (QOL-B) is the first diseasespecific, patient-reported outcome measure for patients with bronchiectasis. Content validity, cognitive testing, responsivity to open-label treatment, and psychometric analyses are presented. METHODS: Reviews of literature, existing measures, and physician input were used to generate the initial QOL-B. Modifications following preliminary cognitive testing (N 5 35 patients with bronchiectasis) generated version (V) 1.0. An open-ended patient interview study (N 5 28) provided additional information and was content analyzed to derive saturation matrices, which summarized all disease-related topics mentioned by each participant. This resulted in QOL-B V2.0. Psychometric analyses were carried out using results from an open-label phase 2 trial, in which 89 patients were enrolled and treated with aztreonam for inhalation solution. Responsivity to open-label treatment was observed. Additional analyses generated QOL-B V3.0, with 37 items on eight scales: respiratory symptoms; physical, role, emotional, and social functioning; vitality; health perceptions; and treatment burden. For each scale, scores are standardized on a 0-to-100-point scale; higher scores indicate better health-related quality of life. No total score is calculated. A final cognitive testing study (N 5 40) resulted in a minor change to one social functioning scale item (QOL-B V3.1). RESULTS: Content validity, cognitive testing, responsivity to open-label treatment, and initial psychometric analyses supported QOL-B items and structure. CONCLUSIONS: This interim QOL-B is a promising tool for evaluating the efficacy of new therapies for patients with bronchiectasis and for measuring symptoms, functioning, and quality of life in these patients on a routine basis. A final psychometric validation study is needed and is forthcoming. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT00805025; URL: www.clinicaltrials.gov

AB - BACKGROUND: The Quality of Life Questionnaire-Bronchiectasis (QOL-B) is the first diseasespecific, patient-reported outcome measure for patients with bronchiectasis. Content validity, cognitive testing, responsivity to open-label treatment, and psychometric analyses are presented. METHODS: Reviews of literature, existing measures, and physician input were used to generate the initial QOL-B. Modifications following preliminary cognitive testing (N 5 35 patients with bronchiectasis) generated version (V) 1.0. An open-ended patient interview study (N 5 28) provided additional information and was content analyzed to derive saturation matrices, which summarized all disease-related topics mentioned by each participant. This resulted in QOL-B V2.0. Psychometric analyses were carried out using results from an open-label phase 2 trial, in which 89 patients were enrolled and treated with aztreonam for inhalation solution. Responsivity to open-label treatment was observed. Additional analyses generated QOL-B V3.0, with 37 items on eight scales: respiratory symptoms; physical, role, emotional, and social functioning; vitality; health perceptions; and treatment burden. For each scale, scores are standardized on a 0-to-100-point scale; higher scores indicate better health-related quality of life. No total score is calculated. A final cognitive testing study (N 5 40) resulted in a minor change to one social functioning scale item (QOL-B V3.1). RESULTS: Content validity, cognitive testing, responsivity to open-label treatment, and initial psychometric analyses supported QOL-B items and structure. CONCLUSIONS: This interim QOL-B is a promising tool for evaluating the efficacy of new therapies for patients with bronchiectasis and for measuring symptoms, functioning, and quality of life in these patients on a routine basis. A final psychometric validation study is needed and is forthcoming. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT00805025; URL: www.clinicaltrials.gov

UR - http://www.scopus.com/inward/record.url?scp=84904000178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904000178&partnerID=8YFLogxK

U2 - 10.1378/chest.13-1891

DO - 10.1378/chest.13-1891

M3 - Article

VL - 146

SP - 437

EP - 448

JO - Chest

JF - Chest

SN - 0012-3692

IS - 2

ER -